🏆 Foundational Paper

Osteoblast-Secreted Factors Mediate Dormancy of Metastatic Prostate Cancer in the Bone via Activation of the TGFβRIII-p38MAPK-pS249/T252RB Pathway.

Yu-Lee Li-Yuan, Yu Guoyu, Lee Yu-Chen, Lin Song-Chang, Pan Jing, Pan Tianhong, Yu Kai-Jie, Liu Bin, Creighton Chad J, Rodriguez-Canales Jaime, Villalobos Pamela A, Wistuba Ignacio I, de Nadal Eulalia, Posas Francesc, Gallick Gary E, Lin Sue-Hwa

📰 Cancer research 📅 2018 📊 146 citations

Abstract

Abstract Bone metastasis from prostate cancer can occur years after prostatectomy, due to reactivation of dormant disseminated tumor cells (DTC) in the bone, yet the mechanism by which DTCs are initially induced into a dormant state in the bone remains to be elucidated. We show here that the bone microenvironment confers dormancy to C4-2B4 prostate cancer cells, as they become dormant when injected into mouse femurs but not under the skin. Live-cell imaging of dormant cells at the single-cell level revealed that conditioned medium from differentiated, but not undifferentiated, osteoblasts induced C4-2B4 cellular quiescence, suggesting that differentiated osteoblasts present locally around the tumor cells in the bone conferred dormancy to prostate cancer cells. Gene array analyses identified GDF10 and TGFβ2 among osteoblast-secreted proteins that induced quiescence of C4-2B4, C4-2b, and PC3-mm2, but not 22RV1 or BPH-1 cells, indicating prostate cancer tumor cells differ in their dormancy response. TGFβ2 and GDF10 induced dormancy through TGFβRIII to activate phospho-p38MAPK, which phosphorylates retinoblastoma (RB) at the novel N-terminal S249/T252 sites to block prostate cancer cell proliferation. Consistently, expression of dominant-negative p38MAPK in C4-2b and C4-2B4 prostate cancer cell lines abolished tumor cell dormancy both in vitro and in vivo. Lower TGFβRIII expression in patients with prostate cancer correlated with increased metastatic potential and decreased survival rates. Together, our results identify a dormancy mechanism by which DTCs are induced into a dormant state through TGFβRIII–p38MAPK–pS249/pT252–RB signaling and offer a rationale for developing strategies to prevent prostate cancer recurrence in the bone. Significance: These findings provide mechanistic insights into the dormancy of metastatic prostate cancer in the bone and offer a rationale for developing strategies to prevent prostate cancer recurrence in the bone. Cancer Res; 78(11); 2911–24. ©2018 AACR.

🔬 Techniques

🔭 Microscopes

💻 Software

✨ Fluorophores

🧪 Sample Preparation

🔬 Cell Lines

🏭 Microscope Brands

Nikon Olympus Leica

🧪 Reagent Suppliers

💻 Software Details

Image Acquisition:
NIS-Elements FluoView
Image Analysis:
NIS-Elements

💾 Data Repositories

🏛️ Research Organizations (ROR)

Affiliated research institutions:

📋 Methods

✔ Verified methods section 743 words Read on PMC ↗

Cell lines, antibodies and reagents Cell lines: Human PCa C4-2B4 (gift from Robert Sikes, University of Delaware, 2006) ( 3 , 4 ), C4-2b (gift from Leland Chung, Cedars-Sinai Medical Center, 2004) ( 5 ), PC3-mm2 (gift from Isaiah J. Fidler, M.D. Anderson Cancer Center, 2005), 22Rv1 (ATCC, 2015) ( 6 , 7 ), and BPH-1 (gift from Simon Hayward, Vanderbilt University, 2015); mouse osteoblast precursor MC3T3 (ATCC, 2006); human lung carcinoma A549 (ATCC, 2013). The identity of all cell lines was verified by polymorphic Short Tandem Repeat loci (STR) profiling, and all cell lines are mycoplasma free. Recombinant human proteins: TGFβ2, TGFβ1, GDF10 (BMP-3b) (R&D). Antibodies: phospho-p38MAPK, p38MAPK, RB, Smad2/3, phospho-Smad1/5, p27Kip1, GAPDH, β-actin (Cell Signaling); phospho(S249/T252)-RB ( 8 ); Ki-67 (Dako); TGFβ2 and TGFβRIII (Proteintech); GDF10, p21 and TGFβRIII (R&D); β-tubulin, α-tubulin (GeneTex). Reagents: mouse TGFβ2 (Genorise) and osteocalcin (Alfa Aesar) ELISA kits; p38MAPK inhibitor SB202190 (InvivoGen); Vybrant DiO lipophilic membrane dye (Invitrogen). Subcutaneous, intra-femural, and intracardiac injection of PCa cells Luciferase-expressing PCa cells were injected under the skin, into the femurs ( 9 ), or into the left ventricle ( 10 ) of male SCID mice. Tumor growth was monitored using bioluminescence imaging. Animal studies were performed in accordance with as well as approved by an Institutional Animal Care and Use Committee (IACUC).

Immunohistochemistry

Tumor bearing femurs were fixed in formaldehyde and decalcified with formic acid before embedded in paraffin. Immunohistochemistry was performed as described ( 11 ). Differentiation of primary mouse osteoblasts Primary mouse osteoblasts (PMOs) were isolated from calvariae of 2-5 day-old pups, cultured to confluence, and the medium switched to differentiation medium, which contains ascorbic acid and β-glycerol phosphate. Osteoblast conditioned medium (OB-CM) was concentrated and medium exchanged by Centricon (Millipore) centrifugation.

Show full methods section

Cell lines, antibodies and reagents Cell lines: Human PCa C4-2B4 (gift from Robert Sikes, University of Delaware, 2006) ( 3 , 4 ), C4-2b (gift from Leland Chung, Cedars-Sinai Medical Center, 2004) ( 5 ), PC3-mm2 (gift from Isaiah J. Fidler, M.D. Anderson Cancer Center, 2005), 22Rv1 (ATCC, 2015) ( 6 , 7 ), and BPH-1 (gift from Simon Hayward, Vanderbilt University, 2015); mouse osteoblast precursor MC3T3 (ATCC, 2006); human lung carcinoma A549 (ATCC, 2013). The identity of all cell lines was verified by polymorphic Short Tandem Repeat loci (STR) profiling, and all cell lines are mycoplasma free. Recombinant human proteins: TGFβ2, TGFβ1, GDF10 (BMP-3b) (R&D). Antibodies: phospho-p38MAPK, p38MAPK, RB, Smad2/3, phospho-Smad1/5, p27Kip1, GAPDH, β-actin (Cell Signaling); phospho(S249/T252)-RB ( 8 ); Ki-67 (Dako); TGFβ2 and TGFβRIII (Proteintech); GDF10, p21 and TGFβRIII (R&D); β-tubulin, α-tubulin (GeneTex). Reagents: mouse TGFβ2 (Genorise) and osteocalcin (Alfa Aesar) ELISA kits; p38MAPK inhibitor SB202190 (InvivoGen); Vybrant DiO lipophilic membrane dye (Invitrogen). Subcutaneous, intra-femural, and intracardiac injection of PCa cells Luciferase-expressing PCa cells were injected under the skin, into the femurs ( 9 ), or into the left ventricle ( 10 ) of male SCID mice. Tumor growth was monitored using bioluminescence imaging. Animal studies were performed in accordance with as well as approved by an Institutional Animal Care and Use Committee (IACUC).

Immunohistochemistry

Tumor bearing femurs were fixed in formaldehyde and decalcified with formic acid before embedded in paraffin. Immunohistochemistry was performed as described ( 11 ). Differentiation of primary mouse osteoblasts Primary mouse osteoblasts (PMOs) were isolated from calvariae of 2-5 day-old pups, cultured to confluence, and the medium switched to differentiation medium, which contains ascorbic acid and β-glycerol phosphate. Osteoblast conditioned medium (OB-CM) was concentrated and medium exchanged by Centricon (Millipore) centrifugation.

Gene array analysis

RNAs prepared from undifferentiated and differentiated PMOs were subjected to whole-genome microarray analysis (4×44K, Agilent Technologies) (Arraystar, Inc). Array data are deposited in NCBI GEO under accession number GSE90127 . PCR RNAs from PMOs were analyzed by qRT-PCR using mouse primers ( Supplementary Table S1 ). Total DNA was prepared from mouse hind legs and used for real-time PCR using primers for human Alu repetitive sequences ( Supplementary Table S1 ). The number of tumor cells in bone was calculated based on Alu PCR of a serial dilution of DNA from C4-2B4 cells.

Live-cell time-lapse imaging

PCa cells were plated in Hi-Q4 dishes (Ibidi) and cultured in RPMI-1650 containing 1:20 dilution of Day 0, 6, 24 or 30 OB-CM or in RPMI-1640 containing 0.1% FBS with TGFβ2, GDF10 or TGFβ1. Images were acquired every 20 min for 72 h in a BioStation (Nikon). Grid-500 glass-bottom dishes (Ibidi) were used for live-cell monitoring in more fields. Data were compiled using NIS-Elements (Nikon) software.

Immunofluorescence imaging

Following live-cell imaging, cells were fixed and permeabilized, co-incubated with anti-Ki67 and anti-p27, and re-imaged on the BioStation. Proximity ligation assay (PLA) Proximity ligation assay was performed using Duolink PLA In Situ Green Starter Kit (Mouse DUO92004/Rabbit DUO92004, Sigma). Primary antibodies were anti-phospho-p38MAPK (28B10) and anti-phospho-(S249/T252)-RB ( 8 ). Images were acquired using FluoView 1000 IX2 confocal microscopy (Olympus).

Generation of C4-2B4 cells with knockdown of TGFβRIII

TGFβRIII was knocked down by RNA interference via lentivirus-expressing shRNAs in pGIPZ. Clones C4-2B4-pGIPZ-sh-TβRIII #2 and #3 were generated. Antisense sequences for sh-TβRIII Clone #2: 5′-ATAGCTCCATGTTGAAGGT-3′ ( NM_001195683 ) and Clone #3: 5′-ATAGTAGACCACACCATCA-3′ (MN_003243).

Generation of C4-2B4 and C4-2b cells with dominant-negative p38MAPK

C4-2B4 and C4-2b cells were transduced with retroviral-expressing p38α dominant-negative MAPK (p38DN), containing mutations in the activation loop between the two kinase domains, from Thr180-Gly-Tyr182 to Ala180-Gly-Phe182 ( 12 ), in a pBMN-I-GFP vector. Human PCa datasets The Kaplan-Meier method with log-rank test was used to evaluate overall disease-specific survival curves for PCa patients from the Nakagawa dataset ( 13 ). Patients from the Taylor data set ( 14 ) were used to evaluate PCa metastasis. Patients from the Lapointe dataset ( 15 ) were used to evaluate PCa metastatic progression. For computing TGFBR3 gene score based on expression profiling data from human PCa tumors, TGFBR3 gene was first z -normalized to SD from the median across the primary tumor samples. The average of the z -normalized values was used to represent the score for each sample profile.

Statistical analysis

Data quantification was performed by using the Student’s t -test and expressed as mean ± s.e.m. P values of < 0.05 were considered statistically significant.

Supplementary Material 1 2 3 4 5 6 7 8

📊 Figures

Figure 1

Osteoblasts in bone microenvironment confer dormancy on C4-2B4 tumor

(A) C4-2B4-LT cells (1 u00d7 10 6 ) were injected subcutaneously (subcu) (n=10) or into the femur of SCID mice (n=10). Tumor growth was monitored by bioluminescence. Consecutive tissue sections were s...

Figure 2

Gene array analyses of osteoblasts before and after culturing in differentiation medium for 30 days

(A) RNAs from undifferentiated (Day 0) or differentiated (Day 30) osteoblasts were used in a whole-genome microarray analysis. 42 transcripts encoding secreted factors upregulated in Day 30 osteoblast...

Figure 3

TGFu03b22 and GDF10 induce PCa cellular quiescence in vitro

(A) C4-2B4 cells treated with TGFu03b22, GDF10 or TGFu03b21 for 72 h were analyzed by live-cell imaging. Quiescent cells that did not divide in 60u201372 h relative to total cells counted were quantif...

Figure 4

TGFu03b2RIII receptor and activation of p38MAPK signaling mediate TGFu03b22 and GDF10 dormancy-inducing effects in PCa cells

(A) TGFu03b2RIII levels in knockdown clones C4-2B4-shTu03b2RIII-#2 and #3 were analyzed by immunoprecipitation followed by immunoblotting, quantified against pGIPZ-sh-Vector cells, and signals normali...

Figure 5

Phospho-p38MAPK and novel N-terminal phospho-S249/T252-RB colocalize in the nucleus of TGFu03b22- or GDF10-treated C4-2B4 cells

(A) C4-2B4 cells were treated with 50 ng/ml TGFu03b22 or GDF10 and co-immunostained for p-p38 and phospho-S249/T252-RB ( 8 ). (B) Cells treated as in (A) for 180 min were co-immunostained as in (A), f...

Figure 6

Dominant-negative p38MAPK prevents dormancy induction by TGFu03b22 or GDF10 in PCa cells in vitro

(A) C4-2B4 cells stably-expressing empty vector or p38DN were examined by western blot for p-p38 followed by p38MAPK. u03b2-tubulin, loading control. (B) Cells in (A) were treated with 50 ng/ml TGFu03...

Figure 7

Dominant-negative p38MAPK prevents dormancy in vivo and lower TGFu03b2RIII expression is associated with poor survival rates in human PCa

(A) Intrabone injection. C4-2B4-Vector or C4-2B4-p38DN cells (1 x 10 6 ) were injected into the femur of SCID mice (n=5 each). Tumor growth was monitored by bioluminescence and expressed as fold incre...

Figure images are served from the NIH/NLM PubMed Central Open Access Subset or Europe PMC; copyright remains with the publishers and authors.

🏛️ Imaging Facility

🏛️ Baylor College of Medicine

💬 Discussion

0 comments

No comments yet. Be the first to start a discussion!

Leave a Comment

MicroHub Assistant